Combined Pembrolizumab & Quavonlimab (MK-1308A) Versus Other Treatments in People With MSI-High or dMMR Stage IV Colorectal Cancer
https://www.facingourrisk.org/research-clinical-trials/study/181/combined-pembrolizumab-quavonlimab-mk-1308a-versus-other-treatments-in-people-with-msi-high-or-dmmr-stage-iv-colorectal-cancer
Clinicaltrials.gov identifier:
NCT04895722 (https://clinicaltrials.gov/show/NCT04895722)
Stage 4 colorectal cancer
About the Study
This study is no longer recruiting patients.
The purpose of this study is to assess the efficacy and safety of co-formulated pembrolizumab/quavonlimab versus four other treatments in patients with Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic (stage IV) Colorectal Cancer.
This is phase 2, multi-arm, randomized, open-label study. Participants are placed into one of the five study groups by chance. All study participants will know which medication they are receiving during the study.
This Study is Open To:
This study is no longer recruiting patients.
This Study is Not Open To:
This study is no longer recruiting patients.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.